{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:03:10Z","timestamp":1792371790236,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.revmed.2018.11.012","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T10:17:17Z","timestamp":1547201837000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["La maladie de Gaucher\u00a0: quand y penser\u00a0?"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-3824","authenticated-orcid":false,"given":"Y.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6207-2128","authenticated-orcid":false,"given":"J.","family":"Stirnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2018.11.012_bib0380","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","article-title":"Metabolism of clucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher's disease","volume":"18","author":"Brady","year":"1965","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.revmed.2018.11.012_bib0385","first-page":"65","article-title":"Gaucher disease epidemiology and natural history: a comprehensive review of the literature","volume":"22","author":"Nalysnyk","year":"2017","journal-title":"Hematol Amst Neth"},{"key":"10.1016\/j.revmed.2018.11.012_bib0390","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562\u00a0patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0395","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.ymgme.2015.12.193","article-title":"The French Gaucher Disease Registry: clinical characteristics, complications and treatment of 616\u00a0patients","volume":"117","author":"Stirnemann","year":"2016","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2018.11.012_bib0400","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2018.11.012_bib0405","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.11.012_bib0410","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","article-title":"Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6\u00a0and interleukin-10","volume":"90","author":"Allen","year":"1997","journal-title":"QJM Int J Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0415","first-page":"205","article-title":"Cytokines in Gaucher's disease","volume":"10","author":"Barak","year":"1999","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.revmed.2018.11.012_bib0420","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0925-4439(96)00056-7","article-title":"Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease","volume":"1317","author":"Michelakakis","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.revmed.2018.11.012_bib0425","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.revmed.2018.11.012_bib0430","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2018.11.012_bib0435","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2012.04.024","article-title":"The role of saposin C in Gaucher disease","volume":"106","author":"Tamargo","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2018.11.012_bib0440","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2004.08.015","article-title":"Gaucher disease: complexity in a \u201csimple\u201d disorder","volume":"83","author":"Sidransky","year":"2004","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2018.11.012_bib0445","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1148\/radiology.160.3.3526400","article-title":"Gaucher disease: sonographic appearance of the spleen","volume":"160","author":"Hill","year":"1986","journal-title":"Radiology"},{"key":"10.1016\/j.revmed.2018.11.012_bib0450","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10545-010-9070-1","article-title":"High incidence of cholesterol gallstone disease in type 1\u00a0Gaucher disease: characterizing the biliary phenotype of type 1\u00a0Gaucher disease","volume":"33","author":"Taddei","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0750","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.1984.tb04731.x","article-title":"Cutaneous manifestations of Gaucher disease","volume":"111","author":"Goldblatt","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0460","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1096-7192(02)00122-1","article-title":"Pulmonary hypertension in type 1\u00a0Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy","volume":"77","author":"Mistry","year":"2002","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2018.11.012_bib0465","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/ajrccm.157.3.9706057","article-title":"Pulmonary manifestations of Gaucher disease","volume":"157","author":"Santamaria","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0470","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2459\/JCM.0000000000000326","article-title":"The role of cardiac magnetic resonance in assessing the cardiac involvement in Gaucher type 1\u00a0patients: morphological and functional evaluations","volume":"18","author":"Roghi","year":"2017","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0475","doi-asserted-by":"crossref","DOI":"10.1053\/ajkd.2002.33935","article-title":"Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy","volume":"40","author":"Santoro","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0480","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00417-011-1745-2","article-title":"A branch retinal artery occlusion in a patient with Gaucher disease","volume":"250","author":"Bruscolini","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0485","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/09273949309086547","article-title":"Chronic uveitis in Gaucher's disease","volume":"1","author":"Raz","year":"1993","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2018.11.012_bib0490","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","article-title":"Neuronopathic Gaucher disease: demographic and clinical features of 131\u00a0patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry","volume":"33","author":"Tylki-Szyma\u0144ska","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0495","first-page":"1","article-title":"Type 3\u00a0Gaucher disease, diagnostic in adulthood","volume":"13","author":"Detollenaere","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.revmed.2018.11.012_bib0500","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.braindev.2005.04.005","article-title":"Type 2\u00a0Gaucher disease: 15\u00a0new cases and review of the literature","volume":"28","author":"Mignot","year":"2006","journal-title":"Brain Dev"},{"key":"10.1016\/j.revmed.2018.11.012_bib0505","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajmg.a.20117","article-title":"Perinatal-lethal Gaucher disease","volume":"120","author":"Mignot","year":"2003","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.revmed.2018.11.012_bib0510","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Protocole national de diagnostic et de soins pour les maladies rares. Maladie de Gaucher. 2015 [Disponible sur: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2580600\/fr\/maladie-de-gaucher]"},{"key":"10.1016\/j.revmed.2018.11.012_bib0515","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304\u00a0mutant alleles in patients with Type 1\u00a0and Type 3\u00a0Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.revmed.2018.11.012_bib0520","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher Registry: demographics and disease characteristics of 1698\u00a0patients with Gaucherdisease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0525","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bcmd.2003.10.007","article-title":"Effect of enzyme replacement therapy on gammopathies in Gaucher disease","volume":"32","author":"Brautbar","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0530","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","article-title":"Increased incidence of cancer in adult Gaucher disease in Western Europe","volume":"36","author":"de Fost","year":"2006","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0535","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-014-9711-x","article-title":"Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy","volume":"37","author":"van Dussen","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0755","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0545","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bcmd.2012.04.002","article-title":"Ferritinemia during type 1\u00a0Gaucher disease: mechanisms and progression under treatment","volume":"49","author":"Mekinian","year":"2012","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0760","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21721","article-title":"Hyperferritinemia and iron overload in type 1\u00a0Gaucher disease","volume":"85","author":"Stein","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0555","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00330-015-3715-2","article-title":"Bone marrow involvement in Gaucher disease at MRI: what long-term evolution can we expect under enzyme replacement therapy?","volume":"25","author":"Fedida","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0560","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","article-title":"Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging \u2013 initial experience","volume":"229","author":"Maas","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.revmed.2018.11.012_bib0765","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","article-title":"Bone density in type 1\u00a0gaucher disease","volume":"11","author":"Pastores","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.revmed.2018.11.012_bib0570","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1\u00a0Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0575","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0770","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/ana.24781","article-title":"Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's","volume":"80","author":"Liu","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0585","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.revmed.2018.11.012_bib0590","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1001\/archinte.167.11.1189","article-title":"Risk of malignant disease among 1525\u00a0adult male US veterans with Gaucher disease","volume":"167","author":"Landgren","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0595","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10545-018-0142-y","article-title":"Hepatocellular carcinoma in Gaucher disease: an international case series","volume":"41","author":"Regenboog","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0600","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0605","doi-asserted-by":"crossref","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1\u00a0Gaucher disease: the need for greater awareness among Hematologists \u2013 Oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 82, 2017,697\u2013701.","DOI":"10.1002\/ajh.20908"},{"key":"10.1016\/j.revmed.2018.11.012_bib0610","unstructured":"Mehta A, Kuter DJ, Salek SS, Belmatoug N, Bembi B, Bright J, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Early Diagnosis Consensus (GED-C) Delphi initiative. Intern Med J."},{"key":"10.1016\/j.revmed.2018.11.012_bib0615","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency \u2013 macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0620","doi-asserted-by":"crossref","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1\u00a0Gaucher disease. J Bone Miner Res. 22, 2007:119-26.","DOI":"10.1359\/jbmr.061004"},{"key":"10.1016\/j.revmed.2018.11.012_bib0625","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1\u00a0Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0630","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028\u00a0patients with type 1\u00a0Gaucher disease after 2\u00a0to 5\u00a0years of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0635","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1\u00a0Gaucher disease following 10\u00a0years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0640","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1\u00a0Gaucher disease: results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.revmed.2018.11.012_bib0775","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1\u00a0Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin Genet"},{"key":"10.1016\/j.revmed.2018.11.012_bib0650","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ajh.23381","article-title":"Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3\u00a0study","volume":"88","author":"Gonzalez","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0655","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ajh.24012","article-title":"Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: long-term data from phase III clinical trials","volume":"90","author":"Hughes","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0660","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mgg3.339","article-title":"Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1","volume":"6","author":"Cer\u00f3n-Rodr\u00edguez","year":"2018","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0665","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.23382","article-title":"Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease","volume":"88","author":"Ben Turkia","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0670","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of type 2\u00a0Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.revmed.2018.11.012_bib0675","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3346\/jkms.2015.30.4.378","article-title":"A phase 2\u00a0multi-center, open-label, switch-over trial to evaluate the safety and efficacy of abcertin\u00ae in Patients with type 1\u00a0Gaucher disease","volume":"30","author":"Choi","year":"2015","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.revmed.2018.11.012_bib0680","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bcmd.2014.04.002","article-title":"Eliglustat, an investigational oral therapy for Gaucher disease type 1: phase 2\u00a0trial results after 4years of treatment","volume":"53","author":"Lukina","year":"2014","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.revmed.2018.11.012_bib0685","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1\u00a0stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.revmed.2018.11.012_bib0690","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2018.11.012_bib0695","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1\u00a0Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2018.11.012_bib0700","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18\u00a0months of eliglustat therapy in treatment-na\u00efve adults with Gaucher disease type 1: the phase 3\u00a0ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0705","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1\u00a0stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.11.012_bib0710","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.revmed.2018.11.012_bib0715","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00007890-199503000-00011","article-title":"Ten years\u2019 experience of bone marrow transplantation for Gaucher disease","volume":"59","author":"Ringd\u00e9n","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.revmed.2018.11.012_bib0720","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1089\/hum.1998.9.17-2629","article-title":"Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with gaucher disease: in vivo detection of transduced cells without myeloablation","volume":"9","author":"Dunbar","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.revmed.2018.11.012_bib0725","doi-asserted-by":"crossref","first-page":"31380","DOI":"10.1038\/srep31380","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Sanchez-Martinez","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.revmed.2018.11.012_bib0730","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.revmed.2018.11.012_bib0735","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.revmed.2018.11.012_bib0740","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2141.2012.09175.x","article-title":"Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4\u20135\u00a0years","volume":"158","author":"Hollak","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2018.11.012_bib0745","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy","volume":"104","author":"Wenstrup","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2018.11.012_bib0375","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ymgme.2017.08.002","article-title":"Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212\u00a0patients with Gaucher disease and 16\u00a0Gaucher expert physicians","volume":"122","author":"Mehta","year":"2017","journal-title":"Mol Genet Metab"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318311858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866318311858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:40:33Z","timestamp":1759336833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866318311858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0248866318311858"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2018.11.012","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"La maladie de Gaucher\u00a0: quand y penser\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2018.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}